Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

News | Stents Drug Eluting

OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES

May 29, 2018 – Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing ...

May 29, 2018

A slide image from Reddy's presntation at Heart Rhythm 2018, showing thrombus formation on the face of a Watchman LAA Occluder device in an echo image. #HRS2018

Feature | Left Atrial Appendage (LAA) Occluders

May 18, 2018 — Left atrial appendage closure (LAAC) with the transcatheter Watchman device prevents thromboembolism from ...

May 18, 2018

News | Antiplatelet and Anticoagulation Therapies

Lower Oral DOAC Anticoagulant Use Associated With More Thromboembolic Events Than Warfarin

May 18, 2018 — Nearly half of patients prescribed warfarin and just under one third of those using newer direct oral ...

May 18, 2018

Botulinum Toxin (botox) Injection in CABG Patients Reduces AFib After Cardiac Surgery. #HRS2018

News | Atrial Fibrillation

Botulinum Toxin Injection in CABG Patients Reduces AFib After Cardiac Surgery

May 18, 2018 — Three year results of a study found injection of botulinum toxin into epicardial fat pads in ...

May 18, 2018

News | Atrial Fibrillation

First Results Reported from AVIATOR 2 Registry for AFib Patients Undergoing PCI

May 15, 2018 – Results of the AVIATOR 2 international registry data show a discrepancy between physician perception and ...

May 15, 2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

Feature | Cardiovascular Clinical Studies

Psoriasis Therapy Can Reduce Coronary Plaque

May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin ...

May 14, 2018

The blood of patients with familial chylomicronemia syndrome (FCS) can appear milky in color (lipemic) due to the buildup of fat in their body. Image courtesy of Akcea Therapeutics.

Feature | Cardiac Diagnostics | Steven D. Freedman, M.D., Ph.D.

Cross-specialty Care in Management of Familial Chylomicronemia Syndrome

In many cases, the diagnosis and management of patients with rare diseases can require the participation of ...

May 07, 2018

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

Feature | Antiplatelet and Anticoagulation Therapies

FDA Clears First Reversal Agent for Rivaroxaban, Apixaban Anticoagulants

May 7, 2018 — The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first ...

May 07, 2018

Technology | Clinical Decision Support

Point of Care Decision Support Releases New Version of Anticoagulation Software

April 30, 2018 — Point of Care Decision Support (PCDS) announced the release of a new version 2.0 of their ...

April 30, 2018

News | Pharmaceuticals

Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study

April 6, 2018 — Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its ...

April 06, 2018

A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

Feature | ACC | Dave Fornell

Latest Data on Cardiac Technology From ACC.18

There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American College ...

March 27, 2018

News | Peripheral Artery Disease (PAD)

Critical Limb Ischemia Treatment Shows No Improvement at Three Months

March 23, 2018 — Patients with foot ulcers or gangrene who received the experimental drug JVS-100 did not show evidence ...

March 23, 2018

News | ACC

Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

March 22, 2018 — The experimental drug andexanet was associated with control of serious bleeding in patients taking a ...

March 22, 2018

News | ACC

Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure

March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily ...

March 20, 2018

News | ACC

More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease ...

March 20, 2018